JPRN-UMIN000011791尚未招募2 期
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001 - A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pulmonary disorder(idiopathic pulmonary fibrosis,interstitial lung disease, pneumoconiosis, active radiation pneumonia, etc.). 2)known EGFR-TKI resistance gene mutation positive 3)known ALK gene translocation positive 4)history of erlotinib or gefitinib treatment 5)inable of oral drug administration 6)current or previous histoty of hemoptysis(2.5ml)due to NSCLC 7)Risk of hemoptysis patients after thoracic radiation therapy is expected 8)With great vessel invasion 9)1cm or longer cavity in tumor 10)current or previous (within the last 1 year)history of GI perforation 11)history of myocardial infarction and cerebral infarction 12)planned surgery within study term 13)uncontrolled heypertension 14)symptomatic brain metastasis 15)history of drug allergy 16)massive,pleural effusion or ascites 17)uncontrolled infection or serious medical complications 18)active concomitant malignancy 19)mental disorder 20)pregnant or or lactating women or those who declined contraception 21)those judged not suitable by the attending physician
研究者
相似试验
已完成
2 期
Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-squamous, non-small cell lung cancer harboring activating EGFR mutationsadvanced EGFR mutation-positive non-squamous non-small cell lung cancerJPRN-UMIN000015467Department of Thoracic Oncology Osaka Medical Center for Cardiovascular diseases20
已完成
2 期
A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancerJPRN-UMIN000016507Shizuoka cancer center21
已完成
不适用
A phase II study of erlotinib plus bevacizumab in chemo-naive patients aged 75 or older with advanced non-squamous non-small-cell lung cancer harboring sensitive EGFR gene mutations(HSR1501)Advanced non-squamous non-small-cell lung cancerJPRN-UMIN000016904Department of Internal medicine, second division, Hamamatsu Univ. School of Medicine26
进行中（未招募）
不适用
A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapyHistologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histological subtypes: adenocarcinoma, planocellular or squamous cell carcinoma, and anaplastic/high-grade or undifferentiated carcinomaEUCTR2006-001308-35-DKThe Finsen Center, Rigshospitalet63
招募中
2 期
Phase II study evaluating Erlotinib/Bevacizumab therapy as a second line therapy for advanced relapsed EGFR mutation positive non-squamous NSCLC patients who received first line combination therapy including platinum and Bevacizumabnon-squamous non-small-cell lung cancerJPRN-UMIN000009603Respiratory Center, Showa University Northern Yokohama Hospital13